1 follower
Dyve is a clinical-stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout.
Synthekine
3 followers
Caribou Biosciences
2 followers
Vera Therapeutics
2 followers
Neogene Therapeutics
2 followers
Kyverna Therapeutics
7 followers
Day One Biopharmaceuticals
1 follower
Aura Biosciences
1 follower
CG Oncology
1 follower
Aviceda Therapeutics
1 follower
Foresight Diagnostics
1 follower
Slingshot Biosciences
1 follower
Explore companies